| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/22/2006 | CN1242999C Benzo-isoselenazole derivatives and its use |
| 02/22/2006 | CN1242794C Chinese traditional medicine preparation for treating leucemia and solid tumor |
| 02/22/2006 | CN1242790C Composition for improving life quality of cancer patients |
| 02/22/2006 | CN1242751C Medicine for treating lung cancer and preparing method thereof |
| 02/22/2006 | CN1242749C Use of CoCl#-[2] in preparation of drug for treating leukemia |
| 02/22/2006 | CN1242740C Mitoxantrone or mitoxantrone hydrochloride liposome injection and its preparing process |
| 02/21/2006 | US7002027 Drug delivery enhancing agents with cholic acid and monosaccharide groups for treating cancer by gene therapy; tissue or organs having an epithelial membrane |
| 02/21/2006 | US7002022 treatment of neoplastic diseases that respond to inhibition of the vascular endothelial growth factor receptor tyrosine kinase activity; tumors, retinopathy, macular degeneration |
| 02/21/2006 | US7002019 aryl hydrocarbon; oxidation of 4,5-dihydro-1,3-azoles to fully unsaturated ring; heterocyclic ketones |
| 02/21/2006 | US7001991 transferrin-doxorubicin linked with glutaraldehyde; low-toxicity, side-effect reduction |
| 02/21/2006 | US7001980 Monoclonal antibodies directed against the G3BP protein, and uses |
| 02/21/2006 | US7001923 Taxol enhancer compounds |
| 02/21/2006 | US7001917 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents |
| 02/21/2006 | US7001916 Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
| 02/21/2006 | US7001911 Fused cyclic modulators of nuclear hormone receptor function |
| 02/21/2006 | US7001906 Pyrrolo (2,3-B) pyridine derivatives containing Pyran ring, useful as anticancer compounds |
| 02/21/2006 | US7001905 Substituted diarylamines as MEK inhibitors |
| 02/21/2006 | US7001729 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 02/21/2006 | US7001601 keyhole limpet hemocyanin (KLH) and adjuvant (QS-21; saponin derivative); immunogens; for treatment of melanomas |
| 02/21/2006 | CA2395196C Cyclic amp-specific phosphodiesterase inhibitors |
| 02/21/2006 | CA2250258C Novel tetralone or benzopyranone derivatives and process for producing the same |
| 02/16/2006 | WO2006017672A2 2, 8-disubstituted naphthyridine derivatives |
| 02/16/2006 | WO2006016681A2 Crp lowering agent |
| 02/16/2006 | WO2006016657A1 Drug for treating or preventing hcv infection |
| 02/16/2006 | WO2006016582A1 Liquid culture method for inonotus obliquns |
| 02/16/2006 | WO2006016468A1 Method of producing liposome-containing preparation |
| 02/16/2006 | WO2006016276A2 Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor |
| 02/16/2006 | WO2006016069A1 Ruthenium complexes for treating cancers |
| 02/16/2006 | WO2006015886A1 Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2 |
| 02/16/2006 | WO2005097107A8 Diphenyl - indol-2-on compounds and their use in the treatment of cancer |
| 02/16/2006 | WO2005062748A3 Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae |
| 02/16/2006 | WO2004047720A3 Methods of inhibiting angiogensis via modification of a lysyl oxidase |
| 02/16/2006 | WO2003033720A8 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| 02/16/2006 | WO2003025129A3 Neurotransmission-associated proteins |
| 02/16/2006 | US20060036089 33 human secreted proteins |
| 02/16/2006 | US20060036074 Bromodomain protein |
| 02/16/2006 | US20060035979 Inhibitors of transcription factor NF-kappaB |
| 02/16/2006 | US20060035977 Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f |
| 02/16/2006 | US20060035964 Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in hongdoushan |
| 02/16/2006 | US20060035948 e.g. 6-nitro-4-[N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran; protecting neuronal cells from oxidative stress induced cell death by iron or by hydrogen peroxide; antihypoxic agent, neuroprotectant |
| 02/16/2006 | US20060035925 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 02/16/2006 | US20060035920 Chk-1 inhibitors |
| 02/16/2006 | US20060035909 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout |
| 02/16/2006 | US20060035899 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein |
| 02/16/2006 | US20060035896 Inhibitors of lysophosphatidic acid acyltransferase beta (LPAAT- beta ) activity; cancer screening and therapy |
| 02/16/2006 | US20060035878 Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor |
| 02/16/2006 | US20060035875 Remedy for hormone-dependent cancer |
| 02/16/2006 | US20060035868 2' Hydroxy-3'-bromo-3,4,4',5-tetramethoxy-(Z)-stilbene; antimitotic agent; inhibits the assembly of tubulin into microtubules; anticarcinogenic: solid tumor cancers, neovascularization; tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and A-4 (extract from willow tree) |
| 02/16/2006 | US20060035857 Methods and compositions for the diagnosis and treatment of cancer |
| 02/16/2006 | US20060035856 Purified polypeptides having IL-13 receptor activity |
| 02/16/2006 | US20060035855 Purified polypeptides having IL-13 receptor activity |
| 02/16/2006 | US20060035839 Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments |
| 02/16/2006 | US20060035814 Reagents and methods for smooth muscle therapies |
| 02/16/2006 | US20060035340 Fermenting an appropriate microorganism using glucose as a carbon source and operating two chromatographic separation steps wherein ion exchange chromatography is followed by hydrophobic interaction chromatography, wherein the diphtheria toxin has a purity of at least 98%. |
| 02/16/2006 | US20060035331 G-protein coupled receptors |
| 02/16/2006 | US20060035328 Artery-and vein-specific proteins and uses therefor |
| 02/16/2006 | US20060035326 Genes |
| 02/16/2006 | US20060035315 Transporters and ion channels |
| 02/16/2006 | US20060035293 Antibodies, polypeptides and polynucleotides, used for detection, prevention and treatment of diseases caused by gramnegative bacteria |
| 02/16/2006 | US20060035263 DRG11-responsive (DRAGON) gene family |
| 02/16/2006 | US20060035246 Chromogenic in situ hybridization methods, kits, and compositions |
| 02/16/2006 | US20060035212 Molecules inhibiting hepatitis c virus protein synthesis and method for screening same |
| 02/16/2006 | US20060034951 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 02/16/2006 | US20060034938 Therapeutic mixture comprising antisense agents, chemotherapeutic compounds and bile extract for use in treatment of cell proliferative disorders |
| 02/16/2006 | US20060034933 Freeze-dried lecithin nanometer powder injection of ursolic acid and its preparation method |
| 02/16/2006 | US20060034869 Drug for treating liver diseases with the use of hollow protein nanoparticles |
| 02/16/2006 | US20060034863 Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
| 02/16/2006 | US20060034856 Epha2 antigen t epitopes |
| 02/16/2006 | US20060034852 Comprising transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety and an immunoglobulin moiety comprising a heavy chain constant region of an immunoglobulin; interfere with binding of a tumor necrosis factor receptor with its ligand; antitumor agents |
| 02/16/2006 | US20060034837 Method and agents for the prevention, inhibition and therapy of cancers |
| 02/16/2006 | US20060034821 periodically administering neuraminidase to a lukemia patient |
| 02/16/2006 | US20060034817 Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase |
| 02/16/2006 | US20060034811 Melanoma vaccine and methods of making and using same |
| 02/16/2006 | US20060034795 Cytostatic drug composition |
| 02/16/2006 | US20060034773 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy |
| 02/16/2006 | US20060034759 Production and use of novel peptide-based agents with bispecific antibodies |
| 02/16/2006 | DE102004034380A1 Use of a composition comprising a TRAIL protein and an indole or benzimidazole derivative to prepare a medicament for treating pain |
| 02/16/2006 | DE102004033902A1 New tetrahydrocarbazole compounds are neurokinin-1 receptor antagonists useful to treat or prevent e.g. pubertas praecox, hirsutism, polycystic ovary syndrome, hormone dependent neoplastic diseases and Alzheimer's disease |
| 02/16/2006 | CA2576949A1 Pyrazolo[1,5-a]pyrimidine derivatives |
| 02/16/2006 | CA2576627A1 Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2 |
| 02/16/2006 | CA2575617A1 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes |
| 02/16/2006 | CA2575607A1 Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor |
| 02/16/2006 | CA2575571A1 2,8-disubstituted naphthyridine derivatives |
| 02/16/2006 | CA2575486A1 Crystalline polymorph of pipindoxifene hydrochloride monohydrate |
| 02/16/2006 | CA2575447A1 A method of improving anticancer effect of pulsatillae radix and a composition prepared by the method |
| 02/16/2006 | CA2575316A1 Trifluoromethyl substituted benzamides as kinase inhibitors |
| 02/16/2006 | CA2575014A1 Crp lowering agent |
| 02/16/2006 | CA2574597A1 Alpha-ketoglutarates and their use as therapeutic agents |
| 02/16/2006 | CA2572614A1 Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer |
| 02/16/2006 | CA2570324A1 Rage fusion proteins and methods of use |
| 02/15/2006 | EP1626096A2 In vitro method of detecting a cell proliferative disorder involving fibroblast growth factor homologous factor-1 (FHF-1) |
| 02/15/2006 | EP1626084A1 Compositions and methods for the diagnosis of tumours |
| 02/15/2006 | EP1626059A1 Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| 02/15/2006 | EP1626058A1 Compositions and methods for the diagnosis of tumour |
| 02/15/2006 | EP1626056A2 Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity |
| 02/15/2006 | EP1626050A1 Sulfur-containing naphthoylimide derivatives |
| 02/15/2006 | EP1625854A1 Albumin conjugates containing a glucuronic linker |
| 02/15/2006 | EP1625847A1 Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine |
| 02/15/2006 | EP1625218A2 Heparanase-derived peptides for vaccination of tumor patients |
| 02/15/2006 | EP1625149A2 Method and carrier complexes for delivering molecules to cells |